Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Press Enter ↵ to search evidence


     Quick Explanation



    The Shingles Prevention Study (Oxman & Levin, JID 2008) reports that a live attenuated Oka/Merck zoster vaccine in 38,546 adults ≥60 years reduced HZ burden of illness by 61.1% (95% CI 51.1–69.1), PHN incidence by 66.5% (95% CI 47.5–79.2), and HZ incidence by 51.3% (95% CI 44.2–57.6), with only mild injection-site reactions; a rigorously executed but industry-funded, ~3.1-year trial later superseded by the more durable and efficacious recombinant vaccine.


     Long Explanation



    What the Shingles Prevention Study (SPS) Demonstrated

    This supplement article by Oxman and Levin describes VA Cooperative Study #403, a randomized, double-blind, placebo-controlled trial at 22 US sites enrolling 38,546 immunocompetent adults ≥60 years (median 69; 41% female) between November 1998 and September 2001, with mean surveillance of 3.13 years and >95% retention via an automated telephone follow-up system. Diagnosis of suspected zoster cases was adjudicated by a blinded clinical evaluation committee and validated by real-time PCR distinguishing wild-type from Oka vaccine strain; 88.4% of 1,308 suspected cases were PCR-diagnosed, and vaccine-strain virus was never detected in confirmed cases .

    Reported efficacy: HZ burden of illness reduced 61.1% (95% CI 51.1–69.1); PHN incidence reduced 66.5% (95% CI 47.5–79.2; 27 vs 80 cases; 0.46 vs 1.38/1000 person-years); HZ incidence reduced 51.3% (95% CI 44.2–57.6; 5.4 vs 11.1/1000 p-y). Efficacy against HZ incidence was lower in subjects ≥70, while PHN efficacy was preserved across age strata. Safety signals were limited to injection-site reactions (erythema 36%, pain/tenderness 35%); post-vaccination SAE rates in the adverse-event substudy were 1.9% (vaccine) vs 1.3% (placebo, P=.034) with no clinically meaningful differences on subject-by-subject review .

    Critical Assessment

    Strengths are genuine: massive randomized sample, active monthly surveillance, laboratory confirmation distinguishing wild-type from vaccine strain, blinded adjudication, and prespecified success criteria. The Zoster Brief Pain Inventory–derived severity-by-duration endpoint (HZ BOI) is innovative but composite—it pools incidence and severity, so component effects (51.3% incidence reduction plus modest severity reduction, 141.2 vs 180.5 mean score) must be disaggregated, as the authors themselves do .

    Conflicts of interest are substantial and disclosed: the study chairman's trial was partly funded by Merck, coauthor Levin held a partial patent interest in the vaccine and sat on Merck's speakers' bureau, and the supplement itself was sponsored by Osaka University Biken, GlaxoSmithKline, the Sabin Vaccine Institute, CDC, and the March of Dimes . Only 0.6% of subjects were lost to follow-up, but immunocompromised persons—a group at highest HZ risk—were excluded, limiting generalizability, and the ~3.1-year window leaves durability unknown. Later observational work showed live-vaccine effectiveness waning from 49.1% in year 1 to 31.8% by year 8, and one review reports 4.2% effectiveness by year 8 for Zostavax, while the recombinant adjuvanted vaccine (ZOE-50/70) achieved 97.2% (age ≥50) and 89.8% (age ≥70) with ~89% long-term efficacy through ~9.6 years .

    An independent 2005 Antelope Valley analysis (lower-quality journal, methodology caveats) also raised the hypothesis that universal childhood varicella vaccination reduces exogenous immune boosting and could elevate adult HZ incidence—a confounder the SPS did not measure, and which the paper acknowledges as a hypothesis from other investigators .

    Bottom line: For its population (immunocompetent US adults ≥60) and its ~3-year window, the SPS provides strong, internally consistent randomized evidence that the live attenuated vaccine reduced HZ-related pain morbidity and PHN. Confidence is high for the reported period; it is explicitly not evidence for long-term durability, immunocompromised populations, or superiority over the later recombinant vaccine. What would change the conclusion: equivalent or higher morbidity in vaccine recipients in independent replication, loss of durability, or safety signals outweighing benefits—the waning-effectiveness data partially confirm the durability caveat.



    Feedback:    

    Updated: November 17, 2026



     BGPT Paper Review



    Study Novelty

    90%

    First definitive large-scale randomized proof that boosting waning VZV-CMI in older adults prevents HZ and PHN; the HZ BOI severity-by-duration composite endpoint was novel.



    Scientific Quality

    90%

    Prespecified endpoints, blinded PCR adjudication, 95% retention, and ~38.5k randomized subjects make this exemplary; main critiques are Merck funding, author patent/speaker COIs, exclusion of immunocompromised subjects, and composite endpoint masking.



    Study Generality

    80%

    Directly generalizable to immunocompetent older adults in varicella-endemic settings; less generalizable to immunocompromised, frail, or non-US populations excluded from the trial.



    Study Usefulness

    90%

    Established the evidence base for zoster vaccination policy in older adults and defined the ZBPI/HZ BOI methodology reused in later zoster vaccine trials.



    Study Reproducibility

    80%

    Methods, case adjudication algorithm, PCR assay, and endpoint definitions are published in detail; full participant-level data availability is not stated in this supplement.



    Explanatory Depth

    70%

    Strongly links efficacy to the VZV-CMI decline mechanism (Hope-Simpson lineage) with supporting immunology citations, but provides no direct immunogenicity-correlate analysis within this paper.


    🎁 Authors: Collect 500 Free Science Tokens (≈ $50.0 USD)

    Claim My Author Tokens

    Use for 125 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $50.0 USD)

     Top Data Sources ExportMCP



     Hypothesis Graveyard



    Hypothesis that vaccination merely modified rash severity without reducing incidence: falsified by the SPS, which showed significant 51.3% incidence reduction plus severity reduction among breakthrough cases.


    Hypothesis that antiviral treatment differences explained the morbidity reduction: countered by comparable antiviral use (87% vs 86%) between arms, though residual unmeasured treatment differences cannot be fully excluded.

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT